Perimembranous Ventricular Septal Defect Treatment & Management
- Author: Michael D Taylor, MD, PhD; Chief Editor: Howard S Weber, MD, FSCAI more...
Small perimembranous ventricular septal defects (VSDs) have a spontaneous closure rate of as high as 50% within the first 2 years of life and often do not require medical or surgical management.
Larger defects may become smaller with time. Medical therapy may be required with large membranous VSDs due to excessive left-to-right shunting and CHF. Therapy is directed at alleviating the symptoms of pulmonary overcirculation. Treatment typically includes increased-calorie feedings, diuretics, and, sometimes, an ACE inhibitor.
Diuretic therapy with furosemide is used to lessen volume overload. Significant potassium wasting may warrant the addition of spironolactone or potassium supplementation.
The use of afterload reduction to improve systemic-pulmonary flow ratios may be beneficial in selected cases. ACE inhibitors also inhibit the tissue-based renin-angiotensin system, preventing deleterious remodeling. Be aware that ACE inhibitors have a potassium-sparing effect. When these are used, spironolactone or supplemental potassium should be avoided or judiciously used.
Failure of medical management to alleviate symptoms in the first 6 months of life requires intervention. Growth failure despite optimal medical therapy and maximized calorie intake is the most important evidence of failure of medical therapy. Intervention in VSD is either by surgery or cardiac catheterization. Very large left-to-right shunts are usually electively repaired within the first 6 months of age.
Severe CHF requiring hospitalization indicates the need for early intervention for VSD closure. Surgical closure is also required for any size of VSD with the development of aortic valve regurgitation.
Elevated pulmonary arteriolar resistance of more than 12 Wood units/m2 that does not decrease with oxygen or selective pulmonary vasodilator therapy may be regarded as inoperable.
Diet and activity
Patients with significant CHF may require caloric supplementation with fortified formula or breast milk.
Patients with small perimembranous VSDs have no activity restrictions. Patients with moderate-to-large perimembranous defects and significant symptomatology limit their own exercise activity levels until the defect is repaired. Patients with repaired VSDs and no residual cardiac sequelae have no activity restrictions.
Patients with large or multiple VSDs may be transferred to a tertiary care center for further diagnostic evaluation or surgical intervention.
Consultations with the following specialists may be indicated:
Pediatric cardiothoracic surgeon, if surgery is needed
Surgical repair is the most common intervention currently performed. Surgery is indicated in patients with uncontrolled congestive heart failure symptoms, evidence of increased pulmonary vascular resistance, or the development of aortic valve insufficiency secondary to leaflet prolapse.
Surgical repair of an isolated large ventricular septal defect (VSD) involves closure of the defect with a Gore-Tex patch.
Surgical mortality is now very low (approximately 1%) in neonates and patients older than 6 months with an isolated perimembranous VSD. New surgical approaches using smaller incisions have proven effective in VSD closure.
Cardiac Catheterization and Hybrid Procedures
Devices are being investigated (not currently FDA approved) for the closure of perimembranous ventricular septal defects (VSDs).[5, 6, 7, 8, 9] VSD closure devices typically have 2 asymmetrical, opposing discs (one for the right ventricular side and one for the left ventricular side), which are released during catheterization under fluoroscopic and transesophageal echocardiographic guidance to occlude the defect.
These devices can be placed percutaneously in the cardiac catheterization laboratory or in the operating room during a "hybrid procedure." These procedures are slightly more complicated than closure of muscular VSDs because of the asymmetry of the device, the proximity to the aortic valve, and the presence of conduction tissue near the defect.
Hybrid procedures may involve inserting the device through a very small incision in the free wall of the right ventricle.
Ongoing investigational trials are currently being performed to assess indications for and outcomes in VSD closure with these devices.
One report noted effective closure in children using the Amplatzer asymmetrical perimembranous occluder in 35 patients with a median age of 4.5 years.[8, 10] The defects were 3-8 mm in size, and the size of the occluder varied from 4-12 mm. After 2.5 years, the rate of complete closure was 91%. Two further studies concluded that the procedure is safe, but warrants further study and requires great skill in cases with small infants.[8, 11]
Complications in the study included residual shunting that required surgical closure of the defect subsequent to the insertion of the device and persistent regurgitation across the tricuspid or aortic valve related to the occluder.[8, 10] Conduction abnormalities, primarily heart block, related to the procedure occurred in 20% of the patients. The abnormalities were permanent in all but one of these patients. In a different study of 1046 patients with perimembranous VSD who underwent percutaneous closure using a modified double-disk occluder (MDO), postprocedure complete atrioventricular block (cAVB) occurred in only 1.63% (n=17) of patients, of whom 8 received permanent pacemaker implantation. Patients older than 18 years were more likely to develop cAVB. The investigators noted that lifelong follow-up with periodic electrocardiography monitoring may be necessary owing to the recurrence of cAVB.
More recent findings in retrospective studies with second-generation Amplatzer vascular occluders for closure of perimembranous VSDs reported similar results regarding the safety and efficacy of these devices.[13, 14]
Another retrospective study evaluated 51 patients younger than 1 year with VSD and reported that perventricular device closure of VSDs was safe and effective in this age population as compared with conventional surgical repair with cardiopulmonary bypass. The infants underwent minimally invasive transthoracic device closure under the guidance of transoesophageal echocardiography without cardiopulmonary bypass and had a short rehabilitation period and excellent cosmetic results.
Outpatient Care and Monitoring
Routine inpatient monitoring of infants and children with small perimembranous ventricular septal defects (VSDs) is not necessary.
Manage patients with large VSDs and no CHF on an outpatient basis but consider early surgical closure. Mild to moderate congestive heart failure (CHF) secondary to large left-to-right shunting caused by a VSD is also managed on an outpatient basis.
Small perimembranous VSDs have a more than 50% spontaneous closure rate. Perform serial follow-up care until the VSD closes.
Manage moderately-sized VSDs on an outpatient basis by monitoring for evidence of a reduction in size or a spontaneous closure. Assess patient growth and increased pulmonary artery pressures, and evaluate the need for elective surgical closure.
For routine perimembranous VSDs, antibiotics for the prevention of bacterial endocarditis are no longer recommended by the American Heart Association. A modest risk of endocarditis is still observed; thus, the importance of vigilant oral hygiene should be reinforced. For patients who underwent postsurgical VSD closure utilizing a gortex patch or other material, SBE precautions are recommended for 6 months post closure.
Williams LJ, Correa A, Rasmussen S. Maternal lifestyle factors and risk for ventricular septal defects. Birth Defects Res A Clin Mol Teratol. 2004 Feb. 70(2):59-64. [Medline].
Oberlander TF, Warburton W, Misri S, Riggs W, Aghajanian J, Hertzman C. Major congenital malformations following prenatal exposure to serotonin reuptake inhibitors and benzodiazepines using population-based health data. Birth Defects Res B Dev Reprod Toxicol. 2008 Feb. 83(1):68-76. [Medline].
Chen FL, Hsiung MC, Nanda N, Hsieh KS, Chou MC. Real time three-dimensional echocardiography in assessing ventricular septal defects: an echocardiographic-surgical correlative study. Echocardiography. 2006 Aug. 23(7):562-8. [Medline].
Chessa M, Butera G, Negura D, et al. Transcatheter closure of congenital ventricular septal defects in adult: mid-term results and complications. Int J Cardiol. 2009 Mar 20. 133(1):70-3. [Medline].
Fu YC, Bass J, Amin Z, et al. Transcatheter closure of perimembranous ventricular septal defects using the new Amplatzer membranous VSD occluder: results of the U.S. phase I trial. J Am Coll Cardiol. 2006 Jan 17. 47(2):319-25. [Medline].
Thanopoulos BD. Catheter closure of perimembranous/membranous ventricular septal defects using the Amplatzer occluder device. Pediatr Cardiol. 2005 Jul-Aug. 26(4):311-4. [Medline].
Liu S, Chen F, Ding X, et al. Comparison of results and economic analysis of surgical and transcatheter closure of perimembranous ventricular septal defect. Eur J Cardiothorac Surg. 2012 Dec. 42(6):e157-62. [Medline].
Lee SM, Song JY, Choi JY, et al. Transcatheter closure of perimembranous ventricular septal defect using amplatzer ductal occluder. Catheter Cardiovasc Interv. 2013 Dec 1. 82(7):1141-6. [Medline].
Wang S, Zhuang Z, Zhang H, et al. Perventricular closure of perimembranous ventricular septal defects using the concentric occluder device. Pediatr Cardiol. 2014 Apr. 35(4):580-6. [Medline].
Fischer G, Apostolopoulou SC, Rammos S, Schneider MB, Bjornstad PG, Kramer HH. The Amplatzer Membranous VSD Occluder and the vulnerability of the atrioventricular conduction system. Cardiol Young. 2007 Oct. 17(5):499-504. [Medline].
Tzikas A, Ibrahim R, Velasco-Sanchez D, et al. Transcatheter closure of perimembranous ventricular septal defect with the Amplatzer(®) membranous VSD occluder 2: initial world experience and one-year follow-up. Catheter Cardiovasc Interv. 2014 Mar 1. 83(4):571-80. [Medline].
Bai Y, Xu XD, Li CY, et al. Complete atrioventricular block after percutaneous device closure of perimembranous ventricular septal defect: A single-center experience on 1046 cases. Heart Rhythm. 2015 Oct. 12 (10):2132-40. [Medline].
Hua N, Aquino P, Owada CY. Transcatheter closure of perimembranous ventricular septal defects with the Amplatzer Vascular Plug-II. Cardiol Young. 2015 Oct 26. 1-8. [Medline].
Ebeid MR, Batlivala SP, Salazar JD, et al. Percutaneous closure of perimembranous ventricular septal defects using the second-generation Amplatzer vascular occluders. Am J Cardiol. 2015 Oct 17. [Medline].
Omelchenko A, Gorbatykh Y, Voitov A, et al. Perventricular device closure of ventricular septal defects: results in patients less than 1 year of age†. Interact Cardiovasc Thorac Surg. 2015 Oct 13. [Medline].
Wilson W, Taubert KA, Gewitz M, et al. Prevention of infective endocarditis: guidelines from the American Heart Association: a guideline from the American Heart Association Rheumatic Fever, Endocarditis, and Kawasaki Disease Committee, Council on Cardiovascular Disease in the Young, and the Council on Clinical Cardiology, Council on Cardiovascular Surgery and Anesthesia, and the Quality of Care and Outcomes Research Interdisciplinary Working Group. Circulation. 2007 Oct 9. 116(15):1736-54. [Medline].